2018 Tularaemia Pipeline Review, H1 with Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com
Jun. 11, 2018
DUBLIN--(BUSINESS WIRE)--Jun 11, 2018--The "Tularaemia - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.
This latest pipeline guide provides comprehensive information on the therapeutics under development for Tularaemia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The pipeline guide also reviews of key players involved in therapeutic development for Tularaemia and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.
Companies MentionedAppili Therapeutics Inc Aradigm Corp DynPort Vaccine Company LLC Emergent BioSolutions Inc EpiVax Inc Grifols SA Tetraphase Pharmaceuticals Inc
Key Topics CoveredIntroduction Report Coverage Tularaemia - Overview Tularaemia - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Tularaemia - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Tularaemia - Companies Involved in Therapeutics Development Tularaemia - Drug Profiles
For more information about this report visit https://www.researchandmarkets.com/research/j9kmf5/2018_tularaemia?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180611005922/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Infectious Diseases Drugs
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/11/2018 01:04 PM/DISC: 06/11/2018 01:04 PM